Plasminogen activator inhibitor-1 (PAI-1; SERPINE1) inhibits the plasminogen activators: tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Elevated levels of PAI-1 have been correlated with an increased risk for cardiovascular disease. Pharmacologically suppressing PAI-1 might prevent, or successfully treat PAI-1 related vascular diseases. This can potentially be accomplished by using small RNA molecules (aptamers). This study's goal is to develop RNA aptamers to a region of PAI-1 that will prevent the ability of PAI-1 to interact with the plasminogen activators. The aptamers were generated through a systematic evolution of ligands via exponential enrichment approach that ensures the creation of RNA molecules that bind to our target protein, PAI-1. In vitro assays were used to determine the effect of these aptamers on PAI-1's inhibitory activity. Three aptamers that bind to PAI-1 with affinities in the nanomolar range were isolated. The aptamer clones R10-4 and R10-2 inhibited PAI-1's antiproteolytic activity against tPA and disrupted PAI-1's ability to form a stable covalent complex with tPA. Increasing aptamer concentrations correlated positively with an increase in cleaved PAI-1. To the best of our knowledge, this is the first report of RNA molecules that inhibit the antiproteolytic activity of PAI-1.
Get full access to this article
View all access options for this article.
References
1.
BLAKEC.M., SULLENGERB.A., LAWRENCED.A., and FORTENBERRYY.M. (2009). Antimetastatic potential of PAI-1-specific RNA aptamers. Oligonucleotides, 19, 117–128.
2.
BOMPIANIK.M., MONROED.M., CHURCHF.C., and SULLENGERB.A. (2012). A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J. Thromb. Haemost., 10, 870–880.
DE TAEYEB., SMITHL.H., and VAUGHAND.E. (2005). Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr. Opin. Pharmacol., 5, 149–154.
5.
DURANDM.K., BODKERJ.S., CHRISTENSENA., DUPONTD.M., HANSENM., JENSENJ.K., KJELGAARDS., MATHIASENL., PEDERSENK.E., SKELDALS., WINDT., and ANDREASENP.A. (2004). Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb. Haemost., 91, 438–449.
6.
ELOKDAHH., ABOU-GHARBIAM., HENNANJ.K., MCFARLANEG., MUGFORDC.P., KRISHNAMURTHYG. and CRANDALLD.L. (2004). Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J. Med. Chem., 47, 3491–3494.
GILSA., PEDERSENK.E., SKOTTRUPP., CHRISTENSENA., NAESSENSD., DEINUMJ., ENGHILDJ.J., DECLERCKP.J., and ANDREASENP.A. (2003). Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb. Haemost., 90, 206–217.
11.
GOHILR., PECKG., and SHARMAP. (2009). The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb. Haemost., 102, 360–370.
12.
GORLATOVAN.V., CALEJ.M., ELOKDAHH., LID., FANK., WARNOCKM., CRANDALLD.L., and LAWRENCED.A. (2007). Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J. Biol. Chem., 282, 9288–9296.
13.
GRANTP.J. (2007). Diabetes mellitus as a prothrombotic condition. J. Intern. Med., 262, 157–172.
14.
HAMSTENA., WIMANB., DE FAIREU., and BLOMBACKM. (1985). Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med., 313, 1557–1563.
15.
HEKMANC.M., and LOSKUTOFFD.J. (1985). Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem., 260, 11581–11587.
16.
HENNANJ.K., ELOKDAHH., LEALM., JIA., FRIEDRICHSG.S, MORGANG.A., SWILLOR. E., ANTRILLIT.M., HREHAA., and CRANDALLD.L. (2005). Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J. Pharmacol. Exp. Ther., 314, 710–716.
17.
HENNANJ.K., MORGANG.A., SWILLOR.E., ANTRILLIT.M., MUGFORDC., VLASUKG.P., GARDELLS.J., and CRANDALLD.L. (2008). Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J. Thromb. Haemost., 6, 1558–1564.
18.
IBARRAC.A., BLOUSEG.E., CHRISTIANT.D., and SHOREJ.D. (2004). The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition. J. Biol. Chem., 279, 3643–3650.
19.
IZUHARAY., TAKAHASHIS., NANGAKUM., TAKIZAWAS., ISHIDAH., KUROKAWAK., VAN YPERSELE DE STRIHOUC., HIRAYAMAN., and MIYATAT. (2008). Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler. Thromb. Vasc. Biol., 28, 672–677.
20.
IZUHARAY., YAMAOKAN., KODAMAH., DANT., TAKIZAWAS., HIRAYAMAN., MEGUROK., VAN YPERSELE DE STRIHOUC., and MIYATAT. (2010). A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J. Cereb. Blood Flow Metab., 30, 904–912.
21.
JETERM.L., LYL.V., FORTENBERRYY.M., WHINNAH.C., WHITER.R., RUSCONIC.P., SULLENGERB. A., and CHURCHF.C. (2004). RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Lett., 568, 10–14.
22.
LAWRENCED.A., PALANIAPPANS., STEFANSSONS., OLSONS.T., FRANCIS-CHMURAA.M., SHOREJ.D., and GINSBURGD. (1997). Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J. Biol. Chem., 272, 7676–7680.
23.
LIY., WUH., NIUY., HUY., LIQ., CAOC., and CAIJ. (2013). Development of RNA aptamer-based therapeutic agents. Curr. Med. Chem., 20, 3655–3663.
24.
LINZ., JIANGL., YUANC., JENSENJ.K., ZHANGX., LUOZ., FURIEB.C., FURIEB., ANDREASENP.A., and HUANGM. (2011). Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J. Biol. Chem., 286, 7027–7032.
25.
LINDAHLT.L., SIGURDARDOTTIRO., and WIMANB. (1989). Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb. Haemost., 62, 748–751.
26.
LONGS.B., LONGM.B., WHITER. R., and SULLENGERB.A. (2008). Crystal structure of an RNA aptamer bound to thrombin. RNA, 14, 2504–2512.
27.
MADSENJ.B., DUPONTD.M., ANDERSENT.B., NIELSENA.F., SANGL., BRIXD.M., JENSENJ.K., BROOST., HENDRICKXM.L., CHRISTENSENA., KJEMSJ., and ANDREASENP.A. (2010). RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1. Biochemistry, 49, 4103–4115.
28.
PREISSNERK.T., MAYA.E., WOHNK.D., GERMERM., and KANSES.M. (1997). Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodelling. Thromb. Haemost., 78, 88–95.
29.
RUSCONIC.P., YEHA., LYERLYH.K., LAWSONJ.H., and SULLENGERB.A. (2000). Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb. Haemost., 84, 841–848.
STEFANSSONS., MCMAHONG.A, PETITCLERCE., and LAWRENCED.A. (2003). Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr. Pharm. Des., 9, 1545–1564.
32.
TACHIASK., and MADISONE.L. (1997). Converting tissue type plasminogen activator into a zymogen. Important role of Lys156. J. Biol. Chem., 272, 28–31.
33.
VAN DE CRAENB., SCROYENI., VRANCKXC., COMPERNOLLEG., LIJNENH.R., DECLERCKP.J., and GILSA. (2012). Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. Thromb. Res., 129, e126–133.
34.
VAN GIEZENJ.J., WAHLUNDG., NERME, and ABRAHAMSSONT. (1997). The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb. Haemost., 77, 964–969.
35.
YASUIH., SUZUKIY., SANOH., SUDAT., CHIDAK., DANT., MIYATAT., and URANOT. (2013). TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells. Thromb. Res., 132, 100–105.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
